T Eisen

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. doi request reprint Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
    Tim Eisen
    Cambridge University Health Partners, Cambridge, UK
    Lancet Oncol 13:1055-62. 2012
  2. pmc Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
    B P Fairfax
    Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LJ, UK
    BMC Cancer 12:590. 2012

Collaborators

  • Petri Bono
  • Paul D Nathan
  • B P Fairfax
  • A Protheroe
  • V M Macaulay
  • R Kaplan
  • S Pratap
  • I S D Roberts
  • J Collier
  • A M Meade
  • A W Ritchie

Detail Information

Publications2

  1. doi request reprint Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
    Tim Eisen
    Cambridge University Health Partners, Cambridge, UK
    Lancet Oncol 13:1055-62. 2012
    ..This phase 2, open-label, non-randomised study assessed the safety and efficacy of the multikinase inhibitor regorafenib for treatment of renal-cell carcinoma...
  2. pmc Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
    B P Fairfax
    Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford OX3 7LJ, UK
    BMC Cancer 12:590. 2012
    ..The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort...